Skip to main content
. 2014 Apr 22;4:86. doi: 10.3389/fonc.2014.00086

Table 1.

Chemotherapeutic compounds targeting the homologous recombination DNA repair pathway.

Compound Class Clinical phase Combination
Mirin MRN complex
Adenoviral mutant NBS1 NBS1 Cisplatin
Adenoviral mutant Rad50 Rad50 Cisplatin
Telomelysin MRN complex I/II Monotherapy
Resveratrol MRN complex
Caffeine PIKK
Wortmannin PIKK
Quercetin PI3K
LY294002 ATM and DNA-PKcs
KU-55933 ATM
KU-60019 ATM
CP466722 ATM
KU59403 ATM
UCN-01 Chk1 and Chk2 I Monotherapy or topotecan or cisplatin
XL-844 Chk1 and Chk2 I Monotherapy or gemcitabine
AZD7762 Chk1 and Chk2 I Monotherapy or gemcitabine or irinotecan
PF-00477736 Chk1 I Gemcitabine
SCH900776 Chk1 I/II Monotherapy or cytarabine or gemcitabine
LY2603618 Chk1 I/II Gemcitabine or pemetrexed and cisplatin
LY2606368 Chk1 I Monotherapy
GDC-0425 Chk1 I Monotherapy or gemcitabine
GDC-0575 Chk1 I Monotherapy or gemcitabine
SAR-020106 Chk1
Advexin p53 I/II Monotherapy and chemotherapy drugs
SCH-58500 p53 I/II Monotherapy and chemotherapy drugs
AdDelta24-p53 p53
SG600-p53 p53
OBP-700 p53
CP-31398 Stabilizes p53
PRIMA-1 Stabilizes p53
CDB3 Stabilizes p53
Peptide 46 Stabilizes p53
SCH529074 Stabilizes p53
TDRL-505 RPA
CheSS19 RPA
MCI13E RPA
B02 Rad51
A03 Rad51 and RecA
AI-10 Rad51 and RecA
RI-1 Rad51
RI-2 Rad51
IBR2 Rad51
3-Aminobenzamide PARP1
Olaparib PARP1 I/II/III Monotherapy
Veliparib PARP1 I Topotecan or carboplatin or doxorubicin or irinotecan
Rucaparib PARP1 I/II Monotherapy or temozolomide
CEP-9722 PARP1 and PARP2 I/II Monotherapy or temozolomide
MK-4827 PARP1 I Monotherapy or temozolomide
BMN 673 PARP1 and PARP2 I/II/III Monotherapy or temozolomide or irinotecan